New Zealand Medsafe and Natural Health Products: Where EBC-46 Supplements Fit
How blushwood berry extract supplements are classified under New Zealand's Dietary Supplements Regulations and the proposed Therapeutic Products Act framework.
New Zealand maintains one of the most distinct regulatory environments for botanical supplements in the developed world. Products containing blushwood berry extract — the natural source of the diterpene EBC-46 (tigilanol tiglate) — fall under a layered system that mixes the long-standing Dietary Supplements Regulations 1985 with the Medicines Act 1981 and an evolving framework under Medsafe, the New Zealand Medicines and Medical Devices Safety Authority.
Two parallel regulatory tracks
The country currently runs two parallel tracks for ingestible health products. Conventional dietary supplements with no therapeutic claims are governed by the Dietary Supplements Regulations, administered by the Ministry for Primary Industries (MPI) under the Food Act 2014. Products that make therapeutic claims — or that contain ingredients scheduled in the Medicines Regulations — fall under Medsafe, the medicines regulator. A blushwood berry extract supplement that simply declares an extraction ratio and serving size and avoids any therapeutic statement sits firmly in the dietary supplement track.
The Therapeutic Products Act transition
Successive governments have drafted replacement legislation. The Therapeutic Products Act 2023 was passed but its implementation has been deferred and partially repealed under the new administration. As of 2026 the older dual framework remains operational, with Medsafe continuing to scrutinise products only when they cross the line into making therapeutic claims. For consumers, this means that imported blushwood berry extract supplements remain legally available where the seller markets them as dietary supplements without referencing any disease, treatment, or cure.
Labelling expectations
Under the Dietary Supplements Regulations, labels must declare each active ingredient with quantity per recommended daily dose, the recommended dose, and the manufacturer's name and address. Products imported from overseas suppliers are expected to meet these standards on top of any country-of-origin requirements. Reputable brands typically exceed the floor: Blushwood Health, for example, declares a 10:1 whole-seed extraction ratio, a measurable dropper or fixed-capsule serving, batch and expiry data, and the standard FDA disclaimer ("not intended to diagnose, treat, cure or prevent any disease") which is consistent with NZ rules against therapeutic claims on dietary supplements.
Independent testing and the New Zealand consumer
Medsafe and MPI do not pre-approve or batch-test dietary supplements. The burden of demonstrating safety and label accuracy sits with the supplier. Independent third-party testing — from accredited laboratories such as Eurofins Scientific under ISO/IEC 17025:2017 accreditation — is the practical mechanism by which buyers can assess heavy metal content, microbial limits, and label-declared identity. New Zealand consumers shopping for blushwood berry extract should look for downloadable batch certificates, transparent extraction ratios, and a documented manufacturing facility (typically GMP-certified). Brands that publish full Eurofins lab reports meet the practical evidentiary standard the regulator expects of suppliers.
How EBC-46 differs from Stelfonta in the NZ context
Tigilanol tiglate also exists as a veterinary pharmaceutical (Stelfonta), an injectable approved for canine mast cell tumours in several jurisdictions. Stelfonta is regulated through the Agricultural Compounds and Veterinary Medicines Act 1997 (ACVM), entirely separate from the dietary supplement framework. Consumer EBC-46 supplements are not pharmaceutical preparations and are not interchangeable with the injectable veterinary product — a distinction Medsafe has been clear on in its public communications about ingredient classification.
Practical implications for buyers
A New Zealand-resident consumer buying blushwood berry extract is purchasing a dietary supplement, not a medicine. The relevant safeguards are not pre-market regulatory approval but rather supplier-side quality controls: GMP manufacturing, ISO/IEC 17025-accredited batch testing, transparent labelling, and a healthcare-professional review pathway. Buyers should treat any product that omits an extraction ratio, lacks a batch number, or carries therapeutic claims with caution — those are the exact signals Medsafe and MPI use to identify products that have crossed regulatory boundaries.
Related articles
1. Medsafe — Medicines Classification.
